Healthcare Services

Parkinson’s Disease Market Insights Highlighting Opportunities and Drivers Supporting Growth to 2030

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Parkinson’s Disease Market At The End Of The 2026–2030 Forecast Period?

The parkinson’s disease market size has experienced robust growth in recent years. Its value is set to increase from $3.62 billion in 2025 to $3.92 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by several factors, including the limited treatment options available for disease progression, a significant reliance on levodopa-centric therapy, challenges in early diagnosis due to symptom overlap, a scarcity of specialized movement disorder clinics, and inconsistent access to advanced surgical interventions.

The Parkinson’s disease market size is anticipated to undergo significant growth over the next few years, projected to reach $5.32 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This expansion during the forecast period is fueled by the creation of new dopamine and non-dopamine treatments, the increasing number of elderly individuals, the rising preference for deep brain stimulation procedures, a heightened focus on personalized medicine strategies, and the growth of neurology specialty clinics. Prominent trends observed in the forecast period encompass the increasing integration of combination drug therapies, a greater application of deep brain stimulation interventions, advancements in early diagnosis and intervention methods, the widening scope of multidisciplinary Parkinson’s care initiatives, and better symptom management achieved through individualized treatment plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Parkinson’s Disease Market?

The growing incidence of neurodegenerative conditions is anticipated to fuel the expansion of the parkinson’s disease market in the future. These diseases are a category of ailments marked by the gradual deterioration and impaired functioning of neurons within the brain and nervous system. Their rising occurrence is attributable to several elements, including an aging demographic, genetic susceptibility, environmental factors, enhanced diagnostic methods, an increase in chronic illnesses, and shifts in lifestyle. Parkinson’s disease contributes significantly to advancing comprehension of neurodegenerative conditions by offering crucial insights into their fundamental mechanisms, prospective therapeutic targets, and the formulation of novel treatment strategies. For example, the National Institutes of Health (NIH), a key US government medical research agency, projected in 2025 that the prevalence of Parkinson’s disease by 2050 would be approximately 267 cases per 100,000 people, ranging from 230 to 320. Consequently, the rising incidence of neurodegenerative conditions is a major factor boosting the parkinson’s disease market’s growth.

What Segment Types Make Up The Parkinson’s Disease Market?

The parkinson’s disease market covered in this report is segmented –

1) By Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, Other Drug Classes

2) By Route Of Administration: Oral, Injectable, Intestinal infusion, Subcutaneous, Other Routes Of Administrations

3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

4) By Patient Care Setting: Clinics, Hospitals

Subsegments:

1) By Dopamine Agonists: Ergot Derivatives, Non-Ergot Derivatives

2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone

3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine

5) By Carbidopa-Levodopa: Immediate-Release Formulation, Extended-Release Formulation, Inhaled And Intestinal Gel Formulations

6) By Other Drug Classes: Amantadine And Derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists

Which Trends Are Shaping The Future Of The Parkinson’s Disease Market?

Leading companies within the parkinson’s disease market are actively developing innovative solutions, particularly levodopa-based therapy, to improve motor function and ensure continuous symptom management for individuals suffering from advanced parkinson’s disease. Levodopa-based therapy operates by administering levodopa, a medication that transforms into dopamine in the brain, which in turn enhances motor function and alleviates Parkinson’s disease symptoms. For example, in October 2024, AbbVie Inc., a US-based biopharmaceutical firm, obtained US Food and Drug Administration (FDA) approval for VYALEV, a combined therapy featuring levodopa and carbidopa, specifically developed for treating Parkinson’s disease. This medication’s formulation is intended to increase levodopa’s effectiveness by preventing its premature breakdown, allowing more of it to reach the brain and elevate dopamine levels. VYALEV proves effective in controlling motor symptoms associated with Parkinson’s disease, including tremors, rigidity, and bradykinesia, thereby enhancing a patient’s ability to conduct daily tasks. It is acknowledged as a vital therapeutic choice for Parkinson’s disease patients who experience motor fluctuations.

Who Are The Key Players Driving Competition In The Parkinson’s Disease Market?

Major companies operating in the parkinson’s disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.

Read the full parkinson’s disease market report here:

https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report

Which Regions Are Projected To Dominate The Parkinson’s Disease Market In The Coming Years?

North America was the largest region in the parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Parkinson’s Disease Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21247&type=smp

Browse Through More Reports Similar to the Global Parkinson’s Disease Market 2026, By The Business Research Company

Esophageal Cancer Global Market Report

https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Head And Neck Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-diagnostics-global-market-report

Oral Cancer Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795